drugset
drugset / Trial / NCT06212648

Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension

NCT06212648 ↗

Phase 2 Completed 253 enrolled Shin Poong Pharmaceutical Co. Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

This study purpose is to determine the appropriate combination drug dose by comparing safety and efficacy with placebo, candesartan, and amlodipine monotherapy after 8 weeks of administration of SPC1001 to patients with essential hypertension.

Timeline

Start
2022-03-25
Primary completion
2022-11-27
Completion
2023-01-27

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified 1.25 mg Oral
Subject Amlodipine Other / unclassified 1.67 mg Oral
Subject Amlodipine Other / unclassified 2.5 mg Oral
Subject Amlodipine Other / unclassified 5 mg Oral
Subject Amlodipine Other / unclassified 10 mg Oral
Subject Candesartan Unknown 2 mg Oral
Subject Candesartan Unknown 2.67 mg Oral
Subject Candesartan Unknown 4 mg Oral
Subject Candesartan Unknown 8 mg Oral
Subject Indapamide Small molecule 0.625 mg Oral
Subject Indapamide Small molecule 0.83 mg Oral
Subject Indapamide Small molecule 1.25 mg Oral

Indications

essential hypertension